Pune, Nov. 15, 2022 (GLOBE NEWSWIRE) — According to the latest report released by Growth Plus Reports, the Pruritus Therapeutics Market clock $6.60 billion by 2030. Rapidly rising adoption of digitalization owing to increasing urbanization is a major driver of the Pruritus Therapeutics market. This proprietary information is published by Growth Plus Reports in its report titled “Pruritus Therapeutics Market – Global Outlook & Forecast 2022-2030
Get a sample PDF brochure:
The pruritus treatments market is expected to grow at a substantial CAGR during the forecast period. The prevalence of systemic (cholestasis, hepatic, hematological, neurological, oncological, renal and drug-related) and dermatological (atopic dermatitis, urticaria, cutaneous T cells, psoriasis allergic contact dermatitis) disorders is expected to increase. Moreover, a key driver for market growth is the launch of new products to meet the large unmet medical demands already existing in the market. For example, in April 2020, biopharmaceutical company Menlo Therapeutics Inc. released preliminary results from two ongoing Phase III clinical trials examining the safety and efficacy of once-daily oral serlopitant for the treatment of associated pruritus. prurigo nodularis. Moreover, market growth is expected to be enhanced over the forecast period by the upcoming commercialization by major players of such a variety of pipeline products. Low prices, technical developments, favorable political climates, R&D focused on pharmaceutical company partnerships, and impending patent expirations are some of the factors driving the market expansion. However, calcineurin inhibitors are expected to grow at the fastest CAGR throughout the forecast period due to its high response rate, robust calcineurin inhibitor portfolio, and availability of semi-analogs. -synthetics of these inhibitors.
Excerpts from “Segmentation by type of drug”
On the basis of drug type, the global pruritus treatments market has been segmented into
- Local anesthesia
- Calcineurin inhibitors
Corticosteroids have dominated the global pruritus treatment market due to the fact that corticosteroids are frequently used as first-line treatment. One of the major drivers for market growth in this segment is expected to be the growing demand for over-the-counter topical corticosteroids. However, calcineurin inhibitors are expected to grow at the fastest CAGR over the forecast period owing to their high response rate, strong calcineurin inhibitor portfolio, and accessibility of semi-synthetic analogs. of these inhibitors.
Excerpts from ‘Segmentation by region’
On the basis of region, the global pruritus therapeutics market has been segmented into
- North America
- Asia Pacific
- Rest of the world
The pruritus treatments market is dominated by North America, and this trend is expected to continue throughout the projected period. Due to the climatic circumstances that cause pruritus and the increasing incidence of disease risk factors, the regions have a significant market share. A European company, MC2 Therapeutics, entered into a collaboration agreement with EPI Health, LLC in August 2020 to co-market its Wynzora cream in the US market due to the increasing prevalence of the targeted disease in North American countries. Additionally, according to MC2 Therapeutics, the United States Food and Drug Administration (USFDA) approved Wynzora for the treatment of plaque psoriasis in adults in July 2020. The imminent release of Wynzora cream in the U.S. market is expected to accelerate market expansion. For the treatment of uremic pruritus, MC2 Therapeutics is also developing MC2-25 PAD cream which is currently in phase II. High unmet healthcare demands (curative therapy, enhanced safety profiles, etc.) and a supportive regulatory environment are two other key elements that are expected to contribute to profitable growth throughout the forecast period.
Excerpts from “Competitive Landscape”
Some of the major market players for the global pruritus therapeutics market include
- Therapeutic Cara
- Abbvie, Inc.
- UCB Pharma
- Pfizer, Inc.
- Amgen, Inc.
- Actavis SA
- Chongqing Huapont Pharm Co.Ltd.
- Bayer AG
- UCB Pharma
- Leo Pharma
- Epi Health, LLC
- Galderma Laboratories, Lp.
- Novartis AG
- Mc2 Therapeutics A/S and among others.
These pharma giants have implemented significant business strategies such as rigorous R&D attempts to develop new and affordable therapies, innovative product and service launches, product expansions and strategic collaborations in order to maintain their dominance in the market. market in this era of intense competition.
Find out before you buy this research report:
- Market ecosystem
- Schedule under study
- Historical years – 2020
- Base years – 2021
- Planned years – 2022 to 2030
- Currency used in the report
- RESEARCH METHODOLOGY
- Research approach
- Data collection methodology
- Information source
- Secondary sources
- Primary sources
- Market estimation approach
- From bottom to top
- From top to bottom
- Market Forecast Model
- Limits and assumptions
- PREMIUM OVERVIEW
- Current market trend (COVID-19 outlook)
- Key players and competitive positioning (2021)
- MARKET DYNAMICS
- GLOBAL PRURITIS THERAPEUTIC MARKET – ANALYSIS AND FORECAST, BY DISEASE TYPE
- Allergic contact dermatitis
- atopic dermatitis
- GLOBAL PRURITIS THERAPEUTIC MARKET – ANALYSIS AND FORECAST, BY DRUG TYPE
- Local aesthetics
- Calcineurin inhibitors
- GLOBAL PRURITIS THERAPEUTIC MARKET – ANALYSIS AND FORECAST, BY END USER
REPORT-RELATED VALUE PROPOSITIONS:
- Fueled by free analyst hours and expert interviews with every report
- Comprehensive quantitative and qualitative information at segment and sub-segment level
- Trends and perspectives of the impact of Covid 19
- Granular information at global/regional/country level
- In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment
- Global coverage of the competitive landscape
- Winning imperatives
- Comprehensive coverage of “strategic developments” recorded by major market players
- Distributor Landscape Assessment
- Pipeline assessment
- Pricing information
- Customer evaluation
- Analysis of investments and initiatives
- ‘Company Profile’ of key players
Buy Now Full Report:
Growth+Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).
The Growth+ portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions. that prepare them for future growth and success.
We have been recognized by the prestigious CEO Magazine as “The Most Innovative Market Research Company in the Healthcare Market of 2020.